GoodCap Pharmaceuticals
GoodCap Pharmaceuticals is dedicated to improving the lives of individuals suffering from neuroinflammatory diseases by developing innovative therapeutic formulations. Founded in 2018, the company focuses on addressing the root causes of psychiatric and neurodegenerative disorders, particularly PTSD, through its lead drug candidate, GCAP001.
Industries
Nr. of Employees
small (1-50)
GoodCap Pharmaceuticals
Products
Combination anti-inflammatory neurotherapeutic candidate
A multi-class small-molecule formulation designed to reduce neuroinflammation by downregulating pro-inflammatory cytokines and oxidative mediators; developed as a therapeutic candidate for PTSD and other neuroinflammation-related psychiatric and neurodegenerative disorders.
Peer-reviewed preclinical research portfolio
Published preclinical studies reporting anti-inflammatory effects of combined treatments in rodent models and human tissue/cell systems, including assays measuring cytokine reductions.
Combination anti-inflammatory neurotherapeutic candidate
A multi-class small-molecule formulation designed to reduce neuroinflammation by downregulating pro-inflammatory cytokines and oxidative mediators; developed as a therapeutic candidate for PTSD and other neuroinflammation-related psychiatric and neurodegenerative disorders.
Peer-reviewed preclinical research portfolio
Published preclinical studies reporting anti-inflammatory effects of combined treatments in rodent models and human tissue/cell systems, including assays measuring cytokine reductions.
Services
Preclinical efficacy research
In vivo and in vitro studies to evaluate anti-inflammatory efficacy of combination formulations using rodent neuroinflammation models and human tissue/cell assays.
Formulation development for combination therapeutics
Design and optimization of multi-component formulations at defined ratios to modulate multiple inflammatory pathways.
Intellectual property development
Preparation and prosecution of patent applications covering compositions and methods of use for combination anti-inflammatory therapeutics.
Preclinical efficacy research
In vivo and in vitro studies to evaluate anti-inflammatory efficacy of combination formulations using rodent neuroinflammation models and human tissue/cell assays.
Formulation development for combination therapeutics
Design and optimization of multi-component formulations at defined ratios to modulate multiple inflammatory pathways.
Intellectual property development
Preparation and prosecution of patent applications covering compositions and methods of use for combination anti-inflammatory therapeutics.
Expertise Areas
- Neuroinflammation therapeutics
- Combination drug formulation
- Preclinical in vivo models of neuroinflammation
- 3D human tissue and cell-based anti-inflammatory assays
Key Technologies
- Combination drug formulation
- Cytokine profiling (ELISA)
- Rodent models of neuroinflammation (DSS colitis model)
- 3D human intestinal tissue models